FDA advisory panel unanimously recommends Moderna booster for certain at-risk groups

On Thursday, a Food and Drug Administration advisory committee voted unanimously to recommend Moderna booster shots at a half dose of 50 micrograms for emergency use authorization for similar at-risk groups as the Pfizer booster vaccine. The decision now goes to the FDA, which is expected to make a final decision in the coming days.

Video Transcript

- Do available data support the safety and effectiveness of Moderna COVID-19 vaccine for use under EUA as a booster dose, 50 micrograms mRNA 1273, at least six months after completion of a primary series in the following populations: individuals 65 years of age and older, individuals 18 to 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19, including severe COVID-19?

- OK, I believe that we have all of the results in for all 19 voting members. And I will read them aloud for the record. Dr. Randy Hawkins voted yes. Dr. Cohn voted yes. Dr. Pergam voted yes. Dr. Nelson voted yes. Dr. Moore voted yes. Dr. Fuller voted yes. Dr. Levy voted yes. Dr. Wharton voted yes. Dr. Hildreth voted yes. Dr. Sawyer voted yes. Dr. Kurilla voted yes. Dr. Monto voted yes. Dr. Perlman voted yes. Dr. Lee voted yes. Dr. Meissner voted yes. Dr. Gans voted yes. Dr. Offit voted yes. Dr. Chatterjee voted yes. Dr. Rubin voted yes.

So we do have a unanimous 19 out of 19 yes votes, and that concludes the voting portion.